Regeneron
NASDAQ:REGNBiotechTarrytown, New York, United States · Est. 1988 · 13,000 employees
Regeneron is a biotechnology company that discovers, develops, and commercializes medicines for serious medical conditions using proprietary technologies and platforms.
34
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
44
Indications↗
Distinct diseases across all programs
488
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
Pipeline Snapshot
By Phase
34 drugs in development
Approved1
Phase 37
Phase 219
Phase 16
Preclinical14
By Therapeutic Area
top 6
Oncology
1433%
Metabolic & Endocrine
512%
Rare Disease
37%
Cardiovascular
25%
Hematology
25%
Nephrology
25%
R&D Momentum
92/100
Pipeline Velocity
74/100
Trial Completion Rate
79/100
Pipeline Concentration
18/100
Pipeline Freshness
77/100
Strategic Signals
- ↗Active in Cardiovascular but thin pipeline — potential licensing opportunity
Activity
Recent Activity
Last 14 days
Nov 4, 2026
Active, not recruiting
A Randomized Phase 2 Platform Study to Evaluate Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for the Perioperative Treatment of Patients With Resectable Non-Small Cell Lung Cancer
Nov 4, 2026
Completed
An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients ≥6 Months to <18 Years of Age With Atopic Dermatitis
Nov 3, 2026
Recruiting
A Phase 1/2 Study of REGN5678 (Anti-PSMAxCD28) With or Without Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-Resistant Prostate Cancer and Other Tumors Associated With PSMA Expression
Nov 3, 2026
Recruiting
A Phase 3, Randomized, Double-blind, Placebo-controlled Trial of ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Oct 31, 2026
Active, not recruiting
An Observational Study to Assess the Effectiveness and Safety of Cemiplimab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in Europe (CEMI-LUNG)
Oct 29, 2026
Active, not recruiting
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis
Oct 28, 2026
Available
Compassionate Use or Expanded Access of Mibavademab
Oct 28, 2026
Recruiting
A Dose Escalation Study Investigating Bispecific Antibody Therapy in Patients With Lupus Nephritis
Oct 28, 2026
Recruiting
An Open-Label, Multi-Center Phase I Study to Investigate the Safety and Tolerability of REGN17235 in Patients With Clonal Cytopenia of Undetermined Significance and Low-Risk Myelodysplastic Syndrome With SF3B1 Mutation
Oct 28, 2026
Recruiting
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamic Effects of ALN-ANG3 in Participants With Diabetic Kidney Disease
Details
Company Info
Company Overview
$115.0B
Mkt Cap
$13.5B
Revenue
$6.8B
Cash
CEOLeonard Schleifer
Founded1988
Employees13,000
HQTarrytown, New York, United States
ExchangeNASDAQ:REGN
Websiteregeneron.com
LinkedInCompany Page
Therapeutic Focus
OncologyCardiovascularOphthalmologyRare DiseaseRespiratoryOtherNeurologyMusculoskeletalMetabolic & EndocrineDermatologyImmunologyHematologyGastroenterologyNephrology
Pipeline
Drug Pipeline
Therapeutic Area
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Cardiovascular(2 drugs)
—
—
1
—
1
Cardiovascular(2 drugs)
Gastroenterology(1 drug)
—
1
—
—
—
Gastroenterology(1 drug)
Hematology(2 drugs)
1
—
1
—
—
Hematology(2 drugs)
Immunology(2 drugs)
1
1
—
—
—
Immunology(2 drugs)
Metabolic & Endocrine(5 drugs)
—
—
4
1
—
Metabolic & Endocrine(5 drugs)
Musculoskeletal(1 drug)
1
—
—
—
—
Musculoskeletal(1 drug)
Nephrology(2 drugs)
1
—
1
—
—
Nephrology(2 drugs)
Neurology(1 drug)
1
—
—
—
—
Neurology(1 drug)
Oncology(14 drugs)
8
2
8
3
—
Oncology(14 drugs)
Ophthalmology(1 drug)
—
1
—
—
—
Ophthalmology(1 drug)
Rare Disease(3 drugs)
1
—
—
2
—
Rare Disease(3 drugs)
Unknown / Other(8 drugs)
2
1
5
1
—
Unknown / Other(8 drugs)
Regulatory
Regulatory Timeline
20235 events
FDADec 14
Eylea — EYLEA
Application BLA125387
FDADec 5
Fabhalta — FABHALTA
Application NDA218276
FDAAug 18
Eylea — EYLEA HD
Application BLA761355
FDAAug 18
Eylea — EYLEA HD
Application BLA761355 (BLA)
FDAAug 18
VEOPOZ — VEOPOZ
Application BLA761339 (BLA)
20247 events
FDAOct 10
Eylea — EYLEA
Application BLA125387
FDAOct 10
Eylea — EYLEA HD
Application BLA761355
FDAMay 24
Fabhalta — FABHALTA
Application NDA218276
FDAApr 5
Libtayo — LIBTAYO
Application BLA761097
FDAMar 26
Fabhalta — FABHALTA
Application NDA218276
FDAMar 8
Praluent — PRALUENT
Application BLA125559
FDAMar 6
Libtayo — LIBTAYO
Application BLA761097
20255 events
FDANov 19
Eylea — EYLEA HD
Application BLA761355
FDAOct 29
Libtayo — LIBTAYO
Application BLA761097
FDAOct 9
Praluent — PRALUENT
Application BLA125559
FDAOct 8
Libtayo — LIBTAYO
Application BLA761097
FDAMar 20
Fabhalta — FABHALTA
Application NDA218276
20263 events
FDAAug 31
Libtayo — LIBTAYO
Application BLA761097
FDAJul 16
Fabhalta — FABHALTA
Application NDA218276
FDAApr 2
Eylea — EYLEA HD
Application BLA761355
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)